Teva Pharmaceutical Industries has introduced an authorized generic of ACTOplus met (pioglitazone/metformin tablets) 15mg/500mg, 15mg/850mg. ACTOplus met is marketed by Takeda Pharmaceuticals USA and used with diet and exercise to improve ...
Tags: Teva Pharmaceutical Industries, pioglitazone tablets, metformin tablets
Teva Pharmaceutical Industries has unveiled authorized generic of Actos (pioglitazone-hydrochloride tablets) 15mg, 30mg and 45mg in the US. Actos is marketed by Takeda Pharmaceuticals USA and used with diet and exercise to improve blood ...
The US FDA has approved Novo Nordisk Victoza (liraglutide [rDNA] injection) label to include data showing superior blood sugar control and weight reduction when compared to Januvia (sitagliptin). Label update also includes approval of ...
Tags: Label update, type 2 diabetes, Victoza
Mylan Pharmaceuticals has won final FDA approval for its abbreviated new drug application (ANDA) for Pioglitazone tablets USP, 15mg, 30mg and 45mg. Previously, FDA has also approved the company's ANDA for Pioglitazone Hydrochloride and ...
Ranbaxy Pharmaceuticals,a wholly owned subsidiary of Ranbaxy Laboratories(RLL),has launched authorized generic pioglitazone hydrochloride tablets in the US market under an agreement with Takeda Pharmaceuticals US. Pioglitazone ...
Tags: Ranbaxy Pharmaceuticals, Ranbaxy Laboratories, Takeda Pharmaceuticals
Watson Pharmaceuticals has introduced Pioglitazone Hydrochloride 15mg, 30mg and 45mg tablets, a generic equivalent to Actos. The company began the shipment of the product after winning the final FDA approval. Actos is a prescription ...
Tags: Generic Version, Actos, blood sugar
Pfizer has granted exclusive development and marketing rights to ChemRar group company SatRx for their DPP(1)-IVi compound, PF-00734200 for type 2 diabetes (T2D). T2D is one of the most burdensome chronic non-communicable diseases, which ...
Tags: Satrx Exclusive License, epidemic proportions, R&D portfolio
Teva UK, a part of Teva Pharmaceutical Industries, has announced the launch of generic Irbesartan tablets. Irbesartan, a generic version of Aprovel (Irbesartan) by Sanofi Pharma Bristol-Myers Squibb SNC, is indicated to treat essential ...
Tags: Irbesartan Tablets, antihypertensive medicinal product regimen
Boehringer Ingelheim India and Eli Lilly India is set to launch Linagliptin (brand name trajenta) 5mg film-coated tablets, for Type 2 diabetes in adults, in India. Linagliptin, which is approved in the US, the European Union, Japan and ...
Tags: Diabetes Drug, product of Boehringer, diabetes epidemic
GI Dynamics has gained full approval to initiate ENDO trial for its non-surgical EndoBarrier device from the US Food and Drug Administration (FDA). The EndoBarrier liner, which is implanted into the gut, is a flexible, tube-shaped device ...
Tags: ENDO trial, non-surgical EndoBarrier device, EndoBarrier liner
The US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) of Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin. ...
Tags: FDA, sNDA, pharmaceutical product, clinical development
Boehringer Ingelheim and Eli Lilly and Company have received European Commission marketing authorization for Jentadueto (linagliptin/metformin hydrochloride) tablets. Jentadueto is a new, single-tablet treatment option, taken twice daily, ...
Tags: marketing authorization, Jentadueto tablets, glycemic control
The FDA has approved Novo Nordisk Levemir (insulin detemir [rDNA origin] injection) for use in children with type 1 diabetes. The basal insulin analog is approved for type 1 diabetes patients from age two through adulthood and adult ...
Tags: FDA, Levemir, treatment for type 1 diabetes